
price close busi april
intuit surgic manufactur da vinci robot
system use wide rang minimally-
biomed devic servic
buy holiday gift fundament strong
buy holiday gift fundament strong
bottom line think post-print pullback stock thursday
holiday weekend gift long thu would aggress buyer
invest solidifi domin long-term guidanc portend ep miss
driven materi higher spend firm invest myriad iter
next-gener technolog spur sell-off stock albeit spend
align compani earli spend assert said well
say favor firm decis increas spend innov
creat earn volatil investor use near
term believ pipelin technolog add already-formid davinci
robot ecosystem enabl deal well new competit come
robot surgeri field also expand pie robot surgeri gener
long-term
importantli fundament busi robust remain
go forward estim note procedur growth revenue/
procedur two import metric stori key driver long-term
revenu earn growth view exceed expect quarter
support increas procedur volum guidanc high end prior
rang continu see increas revenu per procedur bullish
long-term indic view indic firm abil penetr case
requir complex instrument ultim gener strong cash flow
posit mix shift dispos revenu stream continu top line
continu drive materi believ favor shift busi toward
recur revenu stream procedur side also via increas
deliveri davinci system oper leas flexibl capit placement
model may complic y/i comp system revenu side
equat think sound strategi allow firm ingrain
ecosystem exist new hospit custom us abroad
wit think isrg oper leas model perhap expand total
placement time serv strengthen domin isrg ecosystem
view
flexibl capit financ model serv augment isrg strong competit
posit initi direct leas model around five year ago
financ option continu gain traction total placement
structur oper leas
increasingli flexibl financ option includ usage-bas model
isrg current high-volum center intuit remain focus drive
davinci market expans ahead impend competit firm abl
leverag balanc sheet drive adopt davinci ecosystem
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
flexibl capit financ model serv augment isrg strong
competit intuit behind establish breadth busi model well
align trend consolid continu play across us
healthcar system provid firm anoth competit advantag
platform eventu enter market continu entrench
major healthcar player ahead time hospit center increasingli
standard intuit ecosystem addit think sp abil
augment isrg current robot surgeri product portfolio via
platform abil access site natur orific thu expand
reach firm domin robot ecosystem medium term
establish entrench top player robot field
high line expect opex spend bullish long-term indic
begin manag outlin plan grow total oper expens
level firm doubl short- long-
term invest addit continu support on-going platform
launch ion sp advanc instrument firm commit addit
resourc drive long-term ou market expans name india taiwan
china scale busi well support technolog
firm commit manag increas
spend expect high end previous state rang y/i opex
growth expect rang level vs
previous think isrg target invest area magnitud invest
set firm drive strong procedur growth longer term new
market well maintain enhanc competit advantag
ou trend japan growth trend remain strong china quota yet hit
model expect japan next sever quarter china begin
materi second half serv tailwind
busi near medium term japan procedur growth exceed
third consecut quarter continu see increas
traction across new reimburs effect april procedur
think initi adopt trend japan portend posit long-term procedur
volum growth region especi given reimburs line
laparoscop level suggest desir perform procedur via robot
approach region strong china firm place three new
system region quarter new system placement
associ recent system quota given somewhat protract
timelin associ tender process expect impact
quota becom pronounc late increasingli
china current repres isrg total revenu see substanti
upsid go forward system instal could potenti nearli tripl region
sp initi limit roll-out on-going announc fda clearanc
urolog surgic procedur da vinci sp singl port system earli
june firm commenc measur launch platform
system total ship us market instal
addit six system bring total instal base manufactur
constraint limit total system placement current quarter date
roughli procedur perform platform follow receipt
urolog indic vast major like cannibalist
isrg current uro busi expect recent approv tor
indic support volum growth increment robot procedur market
expans addit procedur futur sp indic submiss name
buy unchang target price april
biomed devic servic
colorect expect prove import isrg overal
busi augment total procedur growth
guidanc updat manag today refin outlook total
procedur volum growth expect rang high end
firm initi guidanc rang firm reiter
expect pro forma gm rang total opex
expect increas level high end isrg prior
rang firm continu project incom tax rang
figur intuit surgic result vs cg estim consensu project
buy unchang target price april
biomed devic servic
deriv price target appli premium mean large-cap
med-tech price-to-earnings multipl appli ep model
forward ep compound-annual-growth-rate thu aforement target multipl drive
target price-to-earnings appli pro forma ep estim
deriv target
buy unchang target price april
biomed devic servic
p/e/g valuat financi metric use mean ex-outli large-cap med-tech price-to-earnings p/e/g multipl ep pro forma b/c price-to-earnings multipl use group forma price figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price april
biomed devic servic
million except per share total servic total gross total oper oper incom expens pre-tax incom tax expens tax incom net loss attribut nonconttol interest jv- net incom attribut share ep pro-forma calcul xi trade-in programshar base compens intang liabil litig relat invest attribut non-controlling interest net forma ex tax analysisduct adjust sbc ia margin pro margin includ margin pro incom cont figur revenu model
buy unchang target price april
biomed devic servic
total instrument/access total servic total revenu growth modelgrowth rate assumptionsu system unit sale replacements/trad instal base us total total sold ex-oper asp growth rate procedur growth procedur growth procedur growth gener ou urolog gener gynecolog us ww procedur asp revenue/instal system intuit surgic
